Overview
HBOT for post-concussion syndrome has been studied in both sports medicine and military contexts. Results are mixed: Department of Defense trials (2010s) failed to show benefit, but subsequent civilian trials with longer protocols and 2.0 ATA (vs 1.5 ATA DoD) showed significant improvement. Protocol design appears to be a major variable.
Post-concussion syndrome (PCS) is the persistence of concussive symptoms — headache, dizziness, cognitive difficulty, mood changes, sleep disruption — beyond the expected recovery window of 1–3 weeks. A subset of patients experience symptoms lasting months to years. The condition is a significant source of long-term disability in athletes, military personnel, and civilians following mild traumatic brain injury.
HBOT research in this population has evolved in two tracks: Department of Defense studies in military TBI populations (largely at 1.5 ATA with mixed results) and civilian/Efrati-lab studies (typically at 2.0 ATA with more consistent positive results). The pressure difference matters. The DoD BIMA (Brain Injury and Mechanisms of Action of HBOT) studies at 1.5 ATA failed to show significant benefit over sham, generating controversy about HBOT efficacy. Civilian trials at 2.0 ATA — including Harch 2012, Hadanny 2020 — have shown benefit.
The emerging consensus: PCS likely responds to HBOT at pressures of 2.0 ATA and above, over 40+ session courses. Shorter courses and lower pressures (1.5 ATA DoD protocol) may be insufficient to produce clinically meaningful neuroplastic change.
How HBOT Works for This Condition
Mechanisms overlap with TBI generally — angiogenesis in persistently hypoperfused brain regions, reduced neuroinflammation, improved mitochondrial function, and HIF-1α-driven repair signalling. SPECT imaging in post-concussive patients consistently shows regional hypoperfusion that normalises with HBOT in responders.
GRADE Evidence Rating
Same evidence base as TBI (Boussi-Gross, Tal, Harch). Response rates 60–80% in Efrati Lab trials.
| GRADE Domain | Assessment |
|---|---|
| Risk of bias | Moderate |
| Consistency | Mixed |
| Directness | Direct |
| Precision | Moderate |
GRADE methodology: Grading of Recommendations Assessment, Development and Evaluation. See GRADE Working Group.
Clinical Protocol
| Typical protocol | 40 sessions at 2.0 ATA, 90 minutes each |
|---|---|
| Evidence level | Mixed RCTs — Protocol-dependent |
| FDA status | Not FDA-approved |
Civilian/Efrati-protocol PCS treatment: 40 sessions at 2.0 ATA over 8 weeks, with pre- and post-course cognitive and functional assessment. Dod-protocol: 40 sessions at 1.5 ATA (less consistently effective).
Evidence Base
The DoD/BIMA negative trials at 1.5 ATA were widely cited to argue against HBOT efficacy. Later analyses argue these trials were underpowered for the pressure used and did not match the subsequently positive civilian protocols. The 2.0 ATA Efrati-lab-aligned trials show more consistent benefit. UHMS has not formally reviewed PCS as a candidate indication.
Patient Perspective
PCS patients considering HBOT often have months to years of persistent symptoms that have not improved with standard concussion management. Many have tried multiple medications, cognitive rehabilitation, and vestibular therapy before considering HBOT. The commitment to a 40-session course is substantial; realistic expectations about response are important.
Cautions & Considerations
- Protocol pressure matters — 2.0 ATA has stronger evidence than 1.5 ATA.
- Off-label and typically cash-pay.
- Not a substitute for standard concussion management.
- Response variable; not all patients benefit.
Key Research & References
- Harch et al. 2012
- Wolf et al. 2012 (negative DoD trial)
- Hadanny et al. 2020
- Harch et al. 2017 (veterans)
Indexed Studies for This Condition
Linked entries in the HBOT Studies Database.
Frequently Asked Questions
Why did DoD trials show no benefit?
The DoD BIMA studies used 1.5 ATA, which subsequent research suggests may be below the therapeutic threshold for neurological HBOT. Civilian trials at 2.0 ATA have shown more consistent benefit.
How long after a concussion can HBOT help?
The published positive trials have included patients months to years post-concussion. Earlier intervention may or may not be more effective; this is understudied. The chronic PCS population is the typical research focus.
Is HBOT right for every concussion patient?
No. HBOT is studied for patients with persistent (3+ months) post-concussive symptoms that have not improved with standard management. Uncomplicated concussion recovery is self-limiting and does not require HBOT.
Research disclaimer: This article summarises published research for educational purposes only. Nothing here is medical advice. HBOT is a prescription medical treatment that must be administered under physician supervision in appropriately certified chambers. Discuss any treatment decisions with a qualified clinician.